The Supreme Court’s ruling shook up the new oral anticoagulant (NOAC) market in the second quarter of this year.

With Daiichi Sankyo’s ' Lixiana (Edoxaban) still in the lead, 'Eliquis(apixaban),’ which had experienced a decline in sales after its generics were released, made a successful rebound. On the other hand, Eliquis’s generics that had once rapidly expanded its share in the market virtually disappeared. The Supreme Court’s ruling in April had directly affected the disappearance of generics.

The other two NOAC products - ‘'Xarelto (rivaroxaban)’ and ‘Pradaxa (dabigatran)’ - however, saw a continued decline in its prescription performance.

◆Original drug make